DESIGN AND CHARACTERIZATION OF A NATIVE POLYSACCHARIDE CONJUGATE VACCINE AGAINST CRYPTOCOCCUS NEOFORMANS

PA Ramos Irizarry - 2022 - jscholarship.library.jhu.edu
The pathogenic yeast Cryptococcus neoformans is an encapsulated opportunist pathogen
mainly affecting immunocompromised individuals. Although an increasing public health …

Semi-synthetic glycoconjugate vaccine candidate against Cryptococcus neoformans

CJ Crawford, L Liporagi-Lopes, C Coelho… - bioRxiv, 2024 - biorxiv.org
Cryptococcus neoformans is a fungus classified by the World Health Organization as a
critically important pathogen, posing a significant threat to immunocompromised individuals …

[HTML][HTML] Review 3:" Semi-synthetic Glycoconjugate Vaccine Candidate Against Cryptococcus Neoformans"

M Del Poeta - Rapid Reviews Infectious Diseases, 2024 - rrid.mitpress.mit.edu
Cryptococcus neoformans is a fungus classified by the World Health Organization as a
critically important pathogen, posing a significant threat to immunocompromised individuals …

Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human …

RW Maitta, K Datta, A Lees, SS Belouski… - Infection and …, 2004 - Am Soc Microbiol
Peptide mimotopes of capsular polysaccharides have been proposed as antigens for
vaccines against encapsulated pathogens. In this study, we determined the antibody …

Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model

SJN Devi - Vaccine, 1996 - Elsevier
The encapsulated yeast, Cryptococcus neoformans, causes life-threatening
meningoencephalitis in immunocompromised humans, especially in AIDS patients. Fatality …

Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity

SJ Devi, R Schneerson, W Egan, TJ Ulrich… - Infection and …, 1991 - Am Soc Microbiol
We synthesized Cryptococcus neoformans serotype A glucuronoxylomannan (GXM)
conjugate vaccines under conditions suitable for human use to prevent disseminated …

Synthesis of a potential decasaccharide vaccine-candidate against Cryptococcus neoformans infections

LA BAREL, C CRAWFORD, S OSCARSON - eurocarb2023.com
Cryptococcus neoformans causes around a million infections yearly resulting in death for
more than half of the patients.[1, 2] This environmental yeast is particularly deadly to …

Evaluation of Cryptococcus neoformans galactoxylomannan–protein conjugate as vaccine candidate against murine cryptococcosis

SK Chow, A Casadevall - Vaccine, 2011 - Elsevier
Galactoxylomannan (GalXM) is a complex polysaccharide produced by the human
pathogenic fungus Cryptococcus neoformans that mediates profound immunological …

Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan

RW Maitta, K Datta, L Pirofski - Vaccine, 2004 - Elsevier
The efficacy of antibody mediated immunity against Cryptococcus neoformans has not been
established experimentally for human antibodies. Our group has previously shown that …

Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma

A Casadevall, E Dadachova… - … : from human pathogen to …, 2010 - Wiley Online Library
This chapter talks about recent developments in the vaccine field and the publication of two
recent comprehensive reviews that include additional information on the problem of …